Please assess the completion status of the following clinical trial:

Trial Title: A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Histologically confirmed advanced solid tumor type that is FDA approved for treatment with Carboplatin.~* Life expectancy at least 12 wks~* ECOG performance status of 0-2~* Provide written informed~* Adequate organ system function~FEMALES:~* Non-childbearing potential, who has had:~* A hysterectomy~* A bilateral oophorectomy (ovariectomy)~* A bilateral tubal ligation~* Is post-menopausal~* Complete abstinence from sexual intercourse 14 days before, during and at least 21 days after the last dose of investigational product~* Oral contraceptive~* Injectable progestogen~* Implants of levonorgestrel~* Estrogenic vaginal ring~* Percutaneous contraceptive patches~* Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year~* Sole male partner sterilization prior to the female subject's entry - Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/ gel/ film/cream/suppository)~* If lactating: discontinue nursing prior to the first dose, during and for 14 days following the last dose of study drug~Exclusion Criteria:~* History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug.~* Screening with CNS imaging studies (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) is required only if clinically indicated or if the subject has a history of CNS metastases.~* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:~* Active peptic ulcer disease~* Known intraluminal metastatic lesion/s with risk of bleeding~* Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or~* other gastrointestinal conditions with increased risk of perforation~* History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment~* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:~* Malabsorption syndrome~* Major resection of the stomach or small bowel.~* Presence of uncontrolled infection~* Corrected QT interval (QTc) \> 480 msecs using Bazett's formula~* History of any one or more of the following cardiovascular conditions within the past 6 months:~* Cardiac angioplasty or stenting~* Myocardial infarction~* Unstable angina~* Coronary artery bypass graft surgery~* Symptomatic peripheral vascular disease~* Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)~* Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of greater than or equal to 140 mmHg or diastolic blood pressure (DBP) of greater than or equal to 90mmHg\]~Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry.~* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible~* Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)~* Evidence of active bleeding or bleeding diathesis~* Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels~* Hemoptysis within 8 weeks of first dose of study drug~* Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance with study procedures~* Treatment with any of the following anti-cancer therapies:~* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR~* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib~* Any ongoing toxicity from prior anti-cancer therapy that is greater than Grade 1 and/or that is progressing in severity, except alopecia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carboplatin AUC5 + escalating pazopanib (Type: EXPERIMENTAL): Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21

Based on this trial design, predict the completion outcome and termination type (if applicable).